Plant In China Under Scrutiny

CHANGZHOU, CHINA -- The maker of a blood thinner suspected in four U.S.
deaths and allergic reactions in 350 people said Tuesday that its investigation
was focusing more closely on whether something went awry during the processing
of ingredients in China.

Baxter Healthcare Corp. spokeswoman Erin Gardiner said testing had detected
irregularities in samples of the drug, heparin, that were processed in China
from raw material extracted in China. No such irregularities were detected in
heparin made from raw materials from China but processed at a supplier's plant
in Wisconsin

Baxter has said that a Chinese plant here, Changzhou SPL, was the source of
much of the active ingredient in its heparin. The U.S. Food and Drug
Administration said it never inspected the factory because the agency mixed up
the company with another one that has a similar name. Changzhou SPL apparently
wasn't examined by Chinese drug regulators either, because it isn't licensed as
a pharmaceutical manufacturer with the Chinese government.

For the Full Article Click Here.

This is a very troubling article regarding the Chinese regulations regarding healthcare exports. Mistakes like these are unacceptable. China may not be ready to handle the responsibility of being a world super power.

Grade This Post